RxDoctor Payments Data

Franklin Johnson, MD

Dermatology · Baton Rouge, LANPI 1275522328

Payments from drug & device makers

$7,161in general payments, 2019–2025

Across 375 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$773
  • Lilly USA, LLC$658
  • Amgen$645
  • Novartis$508
  • Pfizer$441
  • plus $3K from 27 others

What the payments were for

  • Speaking & faculty fees$4176%
  • Grants$100%
  • Food & beverage$6,65493%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,161 in reported general payments places this provider in the 55th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$168,809
Medicare patients
535
Services billed
4,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast18$92,062
AdbryTralokinumab-Ldrm13$50,114
Minocycline Hcl285$5,241
Betamethasone Dipropionate113$5,129
Ketoconazole158$3,287
Fluocinonide90$2,978
Clobetasol Propionate93$2,694
Triamcinolone Acetonide235$2,274
Fluorouracil29$1,916
Fluticasone Propionate84$1,864
Levocetirizine Dihydrochloride130$1,740
Hydrocortisone189$1,129
Mupirocin111$967
Tretinoin13$961
Metronidazole15$948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$645$92,06218 claims
LEO Pharma Inc.Adbry$179$50,11413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →